INTRODUCTION
According to IASP, pain is defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage". Pain can be categorized according to duration (acute, convalescent, chronic), pathophysiologic mechanisms (physiologic, nociceptive, neuropathic), and clinical context (postsurgical, malignancy related, neuropathic, degenerative). Nociceptive pain is defined as noxious perception resulting from cellular damage following surgical, traumatic, or disease-related injuries. Postoperative pain is a type of acute nociceptive pain. It is also considered as a transient, reversible type of neuropathic pain. The surgical stimulation also leads to peripheral and central sensitization, the mechanism of pain origin. The effective relief of pain is of paramount importance for humanitarian reasons as well as there are significant physiological benefits. Inadequate pain management results in emotional and physical suffering for the patient, sleep disturbance, tachycardia, hypertension, myocardial ischemia and infarction, impaired bowel
movement and respiratory failure. Postoperative pains are not purely nociceptive in nature, and may consist of inflammatory, neurogenic, and visceral components. Opioid analgesics remain the primary pharmacologic therapy for moderate to severe postoperative pain. But their use is limited by adverse effects, such as nausea, urinary retention, vomiting, pruritus and sedation. Local anesthetic techniques are often short-lived or require interventional procedures. The use of NSAIDs and COX-2 inhibitors is limited by complications like gastrointestinal, renal and hematological toxicities. So a single agent or technique cannot be appropriate in the perioperative setting. Therefore a multimodal method is the best method of managing postoperative pain. The concept of preemptive analgesia is a novel approach in the methods of postoperative pain management. Preemptive analgesia is the anti-nociceptive treatment given before the noxious event like surgery to prevent the establishment of altered central processing of afferent input and consequently decreases the incidence of hyperalgesia and allodynia postoperatively. Oral gabapentin is one of the methods of delivering preemptive analgesia. Gabapentin, a structural analog of gamma-aminobutyric acid, has been effective in neuropathic pain, diabetic neuropathy, post herpetic neuralgia and reflex sympathetic dystrophy. Gabapentin has a selective effect on the nociceptive process involving central sensitization. It also reduces the hyper excitability of dorsal horn neurons induced by tissue injury. Thus its pre-treatment is effective in the management of postoperative pain and blocking the development of hyperalgesia. There are pharmacodynamic and pharmacokinetic interactions between morphine and gabapentin, which lead to an augmentation of their analgesic effect. Therefore gabapentin is effective in reducing pain intensity, opioid consumption and opioid-related adverse effects after surgery. Gabapentin has very few adverse effects of its own. With this background, this study has been designed to test the hypothesis that the preoperative use of oral gabapentin will prolong the analgesic effect of epidural morphine without an increase in adverse effects of morphine, and thus reduce consumption of epidural analgesics after elective lower abdominal surgery.

MATERIALS AND METHODS
This is a prospective, randomized, placebo-controlled, double-blinded study conducted at Tribhuvan University Teaching Hospital from 2010 to 2011. After the approval of the Institutional Review Board of Institute of Medicine, Kathmandu, Nepal, the eligible consenting patients were evaluated pre-operatively, and randomly assigned to one of the two study groups using a sealed envelope technique. Each group had a sample size of 30 patients. Inclusion criteria included ASA physical status I and II patients, aged 18 to 65 years, undergoing elective abdominal hysterectomy surgery. The patients were randomized to get either oral placebo tablets or oral gabapentin tablets of dose 1.2 g one hour before surgery. Informed consent was obtained from all the participating patients. Patients with ASA physical status - grade III or more, known history of hypersensitivity to any drug used in this study, history of drug or alcohol abuse, patients having coagulation disorder, patients taking anticoagulants, with history of chronic pain conditions, and who have taken NSAIDs in last 24 hours were excluded. The patients were counseled about methods of measuring postoperative pain, sedation, dizziness, nausea and vomiting, and pruritus. The patients were fasted for six hours preoperatively. They received the study drugs in the morning of the surgery as per the randomization. In the preparation room, baseline systolic and diastolic pressure, heart rate, respiration rate and oxygen saturation were recorded. The epidural catheterization and general anesthesia procedures were conducted according to standard protocol. Intraoperative systolic, diastolic, mean arterial pressure, heart rate and rhythm, and peripheral oxygen saturation readings were monitored.

After completion of surgery, a loading dose of bupivacaine 0.125% with morphine 50 µg per kg body weight with total volume of 8 ml was administered through the epidural catheter. After the end of surgery, patient was transferred to the recovery room. The time in the recovery room when patient was fully conscious was recorded as time 0. Assessments of systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate were done hourly for first 12 hours, then four hourly for the next 12 hours. Assessments of pain, sedation, nausea, vomiting, dizziness and pruritus were performed at 0, 1, 2, 4, 8, 12 and 24 h after arrival in the post anesthesia care unit or postoperative ward. Assessment of postoperative pain was done, at rest and on movement, with
Visual analogue scale (VAS). Patients received postoperative analgesia with an epidural solution containing bupivacaine 0.125% and morphine 50 µg per kg body weight, total volume 8ml when patient complained of pain and VAS was more than three. The time of the first postoperative epidural analgesia injection was recorded. The minimum interval between two successive doses was 30 minutes. Total morphine consumption for each patient was recorded from 0 to 24 h postoperatively. The misplacement of catheter was suspected when pain was not relieved and VAS was > 3 after two consecutive epidural analgesics in the postoperative ward. These patients were excluded from the study. Injection Tramadol 50mg IV was used as rescue analgesia. The epidural morphine administration was stopped in case of a sedation score equaled 3 or respiratory depression.

RESULTS
The mean age in gabapentin group was 42.26 ± 6.8 years, and in control group 44.86 ± 9.25 years. The patients in both the groups were comparable in terms of weight, ASA physical status, heart rates, blood pressure, respiratory rate and oxygen saturation. The majority of the patients in the study underwent total abdominal hysterectomy for fibroid uterus. There was no significant difference in duration of surgery between the gabapentin and placebo group (99.63) ± 24.73 vs. 100±20.02 minutes, p = 0.927). (P =0.855). The mean bolus epidural dose in the gabapentin group was 2.77±0.477 mg while in the placebo group it was 2.79mg ± 0.435 mg (p=0.855). The mean duration of analgesia after the initiation of the epidural analgesia was compared between the two groups. Ten cases in gabapentin group did not need any epidural morphine top up in the 24 hours postoperatively. They were followed further for first analgesia requirement. The mean duration of analgesia after the first dose of epidural analgesia was 1078.26 ± 418.46 minutes in gabapentin group while in the placebo group, it was 303.5 ± 193.72 minutes (p< 0.0001) as shown in figure 1.

There was significant difference in the number of postoperative epidural analgesic top up between gabapentin and placebo groups (P < 0.0001). The mean number of top up in the gabapentin group was 0.7 ± 0.53 while it was 2.26 ± 0.58 in the placebo group. The total amount of morphine consumption was significantly different between gabapentin and placebo group (1.93±1.5 vs. 6.30±1.82 mg, p < 0.0001), shown in figure 2. The VAS scores for pain at both the rest and during movement were significantly lower in the gabapentin group compared with the placebo group. Patients in the gabapentin group had significantly lower VAS scores at all times 0, 1, 2, 4, 8, 12 and 24 hours than those in the placebo group as shown in figure 3. There was no episode of hypotension, bradycardia or respiratory depression in any case in 24 hours postoperatively. In the postoperative period, the
patients in gabapentin group had fewer side effects such as nausea, vomiting, dizziness and pruritus when compared with placebo. The incidence of nausea and pruritus was significantly lower in the gabapentin group compared to the placebo group.

DISCUSSION
Our study shows that the preemptive administration of gabapentin 1200 mg significantly reduces the incidence of pain after abdominal hysterectomy. Postoperatively, patients who received preemptive gabapentin had significantly lower pain scores at 1, 2, 4, 8, 12 and 24 h and had significantly decreased total morphine requirements in the initial 24 h in comparison to the placebo group. The duration of analgesia was also significantly prolonged in the gabapentin group. VAS scores were significantly lower at both the rest and during movement compared to the placebo group. The patients in gabapentin group had fewer side effects such as nausea, vomiting and pruritus when compared with placebo. The incidence of nausea and pruritus was significantly lower in the gabapentin group compared to the placebo group. Our study shows that the preemptive use of gabapentin was effective in our study and other studies have shown similar results. Its use has resulted in the decrease in postoperative morphine consumption. In the study by Dierking G et al. 24 gabapentin 1200mg was given 1h before surgery and followed by gabapentin 600mg 8, 16 and 24h after the initial dose in patients undergoing abdominal hysterectomy. The morphine consumption was reduced by 32% without significant effects on pain scores. The reduction in morphine consumption observed in this study may have been due to an increase in side effects like sedation and dizziness caused by gabapentin. These side effects in turn may have reduced the patients’ desire for morphine consumption. But no such side effects were observed in our study. So it can be said that the decrease in morphine consumption in our study is due to the analgesic interaction between gabapentin and morphine. But the dose of gabapentin in our study is less compared to the dose used in their study (1200mg Vs. 3000mg). The use of lower dose of gabapentin may have been responsible for lesser side effects in our study. In another study Turan et al. 4 evaluated the perioperative use of Gabapentin as a non-opioid analgesic adjuvant for postoperative pain management with patient-controlled epidural
Eckhardt K et al. 22 have proved the reason for decreased consumption of morphine after use of oral gabapentin. The study has shown that gabapentin increases the analgesic effect of morphine. In healthy volunteers undergoing the cold pressure test, 600mg oral gabapentin had no analgesic effect compared with placebo. However, when the same dose of gabapentin was given with morphine, there was an analgesic effect. Serum levels of morphine were higher when volunteers were treated with morphine and gabapentin than when given morphine alone. Thus it appears that gabapentin increases the analgesic effect of morphine. The possible enhancement of morphine analgesia by gabapentin may be useful in decreasing the dose of morphine requirements postoperatively and its adverse effects. The results of our study are similar in that morphine consumption was significantly lower in gabapentin group compared to placebo group.

It is possible that gabapentin could be particularly useful in movement-related pain after surgical trauma because of its ability to prevent central neuronal sensitization. It can be speculated that measuring VAS scores on movement would be more informative than measuring them only at rest. Our study has shown significant decrease in pain scores during movement. Alparslan et al. 25 investigated, in a randomized, placebo-controlled, double-blind study, the efficacy and safety of gabapentin on pain after abdominal hysterectomy and on tramadol consumption. The VAS scores in the sitting and supine position at 1, 4, 8, 12, 16, and 20h were significantly lower in the gabapentin group when compared with the placebo group upto 20h after surgery. These findings are similar to those in our study. The tramadol consumption was significantly less in the gabapentin group. Sedation scores were similar at all the measured times. There were no differences between groups in adverse effects. The study by Verma A et al.26 has shown results similar to our study. Patients receiving 300mg of gabapentin 2 hours before abdominal hysterectomy had significantly lower VAS scores at 2, 4, 8, 12 and 24h postoperatively as compared to the placebo. Total numbers of epidural boluses were significantly less in gabapentin group (3.4 ± 1.6 Vs. 5.6 ± 2.1, P<0.05). Patients were given 12 ml of epidural bupivacaine 0.125% bolus on demand. In our study, the mean number of top up in the gabapentin group was 0.7 ± 0.53 while it was 2.26 ± 0.58 in the placebo group (P<0.0001). The addition of morphine in the dose of 50 µg per kg body weight in the epidural bolus may have decreased the number of epidural boluses in our study. Another study by Dirks J A et al.27 has shown that single dose of oral gabapentin 1200mg resulted in an almost 50% reduction in postoperative morphine consumption, and in a similar reduction in movement-related pain during the first 4h after radical mastectomy without significant side effects, similar to our findings.
our study has shown that gabapentin when given preoperatively has resulted in significant less morphine consumption. The findings are consistent with the studies \(^4\), \(^25\), \(^30\) in which gabapentin was used in the dose of 1200mg, the same dose as used in our study. Pandey et al.\(^29\) and Giron et al.\(^31\) in their study reported a higher incidence of sedation in patients who received gabapentin. In the study by Gilron et al.\(^31\) 17.4% of patients in gabapentin group developed heavy sedation compared to placebo group (P < 0.05). They had used gabapentin in the dose of 1800mg per day for three days, starting preoperatively on the day of surgery and continuing through the postoperative days one and two. Although more patients in gabapentin group developed intermittent sedation in our study compared to placebo group, it was statistically not significant (p = 0.4). The smaller dose of gabapentin in our study may have caused the difference. Although the elimination half-life of gabapentin is between 4.8 and 8.7 h, persistence of sedation even during the latter period of the follow-up indicates that the sedative activity may have been due to epidural morphine instead. Additionally, 63.3 % of patients in the placebo group who did not receive gabapentin also developed intermittent sedation. Therefore the sedative effect cannot be attributed to the use of gabapentin alone. A limitation of our study is that we did not have a dose-response data before choosing the dose of gabapentin in our study. Different studies have used gabapentin in different doses ranging from 300 mg to 3000 mg. Some of the studies have used multiple dosing instead of a single preoperative dose like ours. So the conclusion about the optimal dose and duration of gabapentin cannot be made.

CONCLUSION

From this randomized, double blind, prospective study, we conclude that oral gabapentin, 1200mg as a premedication prolongs the analgesic effect of epidural morphine and decreases the postoperative epidural morphine consumption with significant reduction in pain scores at rest and during movement. As a part of multimodal analgesia, gabapentin is a useful adjuvant to epidural analgesia after total abdominal hysterectomy. Gabapentin can be an effective drug in the armamentarium of anesthesiologists in the treatment of postoperative pain.

REFERENCES


